Clinical Trials

Phase 3 Not yet recruiting

Colonic Neoplasms, Colorectal Neoplasms

NCT07525206 2026-04-13

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

700 enrolled

CNSGastrointestinalGenitourinaryGynecologicSarcoma

Colorectal Neoplasms

NCT05919264 2026-04-09

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

595 enrolled

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT05854498 2026-04-02

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

50 enrolled

Colorectal Neoplasms

NCT06607458 2026-03-13

DEL-LIVER

90 enrolled

Rectal Neoplasms, Colorectal Neoplasms

NCT03223779 2026-03-12

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

Phase 1/2 Completed

52 enrolled

Colorectal Neoplasms

NCT05343013 2026-03-06

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

25 enrolled

Colorectal Neoplasms

NCT04511039 2026-03-02

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Phase 1 Recruiting

45 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Colorectal Neoplasms

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT04109924 2026-02-10

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

42 enrolled 12 charts

Phase 3 Active not recruiting

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05198934 2026-02-06

CodeBreak300

160 enrolled 2 FDA

Colorectal Neoplasms

NCT04776148 2026-02-05

MK-7902-017

563 enrolled 32 charts

Phase 2 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT07381764 2026-02-02

ROMANCE - GOIM

150 enrolled

Colorectal Neoplasms

NCT04457297 2026-01-21

ALTAIR

243 enrolled 13 charts

Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT03844620 2026-01-09

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT06245356 2025-12-10

TRIFLUOX-DP

73 enrolled

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT05600309 2025-11-26

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

94 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05839951 2025-11-12

STAR-T

Completed

818 enrolled

Phase 1 Active not recruiting

Colonic Neoplasms, Colorectal Neoplasms

NCT05029882 2025-10-29

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

520 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05064059 2025-09-17

MK-4280A-007

441 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06887218 2025-08-27

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

57 enrolled

Colorectal Neoplasms

NCT06614192 2025-08-26

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Phase 3 Recruiting

460 enrolled

Colorectal Neoplasms

NCT04166604 2025-08-19

LONGBOARD

176 enrolled

Neutropenia, Colorectal Neoplasms

NCT05328908 2025-08-13

RELATIVITY-123

Phase 3 Terminated

770 enrolled

Phase 2 Not yet recruiting

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07071844 2025-07-17

BETWEEN

162 enrolled

Phase 1 Active not recruiting

Neutropenia, Colorectal Neoplasms

NCT04868773 2025-04-16

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

12 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT04450836 2025-03-30

SOREGATT

Phase 2 Terminated

234 enrolled

Phase 1 Not yet recruiting

Colorectal Neoplasms

NCT06882915 2025-03-19

Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study

20 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

64 enrolled

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04294264 2024-11-18

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

50 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Colonic Neoplasms, Colorectal Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Phase 1 Recruiting

917 enrolled

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT04737187 2024-09-24

SUNLIGHT

492 enrolled 22 charts 2 FDA

Colorectal Neoplasms

NCT06403709 2024-09-24

Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients

35 enrolled

Colorectal Neoplasms

NCT01607957 2024-09-19

RECOURSE

800 enrolled 12 charts

Colorectal Neoplasms

NCT05356897 2024-09-19

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Phase 2 Withdrawn

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02860546 2024-09-03

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

18 enrolled 12 charts

Neoplasm Metastasis, Colorectal Neoplasms

NCT03981614 2024-08-22

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

102 enrolled 11 charts

Colorectal Neoplasms

NCT05223673 2024-08-20

COLSTAR

Phase 3 Terminated

7 enrolled 12 charts

Neoplasm Metastasis, Colorectal Neoplasms

NCT05130060 2024-08-14

A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer

Phase 1 Completed

15 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03520946 2024-08-09

RAMTAS

430 enrolled

Colorectal Neoplasms

NCT03274882 2024-07-25

Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies

26 enrolled

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT06495463 2024-07-10

Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan

Phase NA Unknown

110 enrolled

Colorectal Neoplasms

NCT06485713 2024-07-03

Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

200 enrolled

Colorectal Neoplasms

NCT03992456 2024-05-21

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

12 enrolled 16 charts

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04073615 2024-05-02

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

Phase 1 Terminated

29 enrolled

Colorectal Neoplasms

NCT03317119 2024-04-08

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

Phase 1 Completed

26 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06202001 2024-04-02

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

Phase 1/2 Recruiting

70 enrolled

Phase 3 Not yet recruiting

Colorectal Neoplasms

NCT06343116 2024-04-02

NOTABLE-308

420 enrolled